6-Mercaptopurine Or Azathioprine? by McGovern, D, Travis, S

Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. by Vora, A, Mitchell, C, Lennard, L, Eden, T, Kinsey, SE, Lilleyman, J, Richards, S

“…BACKGROUND: 6-mercaptopurine has been a standard component of long-term continuing treatment for childhood lymphoblastic leukaemia, whereas 6-thioguanine has been mainly used for intensification courses. …”

Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours by Roberts, C, Strauss, VY, Kopijasz, S, Gourley, C, Hall, M, Montes, A, Abraham, J, Clamp, A, Kennedy, R, Banerjee, S, Folkes, LK, Stratford, M, Nicum, S

“…<br><strong>Background: </strong>Tumour cells with BRCA1/2 gene mutations demonstrate increased sensitivity to platinum and poly (ADP-ribose) polymerase (PARP) inhibitors. 6-mercaptopurine (6MP) was found to selectively kill BRCA-defective cells in a xenograft model as effectively as the PARP inhibitor AG014699, even after these cells acquired resistance to a PARP inhibitor or cisplatin.…”

A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol by Nicum, S, Roberts, C, Boyle, L, Kopijasz, S, Gourley, C, Hall, M, Montes, A, Poole, C, Collins, L, Schuh, A, Dutton, S

“…</p> <p><strong>Methods</strong> This multi-centre phase II single arm trial was designed to investigate the activity and safety of 6-mercaptopurine (6MP) 55 mg/m2 per day, and methotrexate 15 mg/m2 per week in patients with advanced breast or ovarian cancer, ECOG PS 0–2, progressing after ≥ one prior regimen and known to bear a BRCA1/2 germ line mutation. …”

Oral methotrexate is as effective as intramuscular in maintenance therapy of acute lymphoblastic leukaemia. by Chessells, J, Leiper, A, Tiedemann, K, Hardisty, R, Richards, S

“…One hundred and forty four children with acute lymphoblastic leukaemia not of the T cell type were randomised to receive continuing treatment with daily 6-mercaptopurine, vincristine, and prednisolone six weekly and methotrexate once weekly, either as a single oral dose or an intramuscular injection. …”

Prognostic importance of myelosuppression during maintenance treatment of lymphoblastic leukaemia. Leukaemia in Childhood Working Party of the Medical Research Council. by Dolan, G, Lilleyman, J, Richards, S

“…Those receiving daily 6-mercaptopurine and weekly methotrexate who were in first remission 20 months from diagnosis were divided into two groups on the basis of whether or not they had ever had an absolute neutrophil count of less than 0.5 x 10(9)/l recorded during maintenance treatment up to that time. …”

Feasibility and efficacy of maintenance chemotherapy following autologous bone marrow transplantation for first remission acute lymphoblastic leukaemia. by Tiley, C, Powles, R, Treleaven, J, Catovsky, D, Milan, S, Teo, C, Catalano, J, Mehta, J, Shields, M, Gupta, P

“…Maintenance chemotherapy was commenced in a total of 26 patients and was tolerated to a median daily dose of 6-mercaptopurine of 40.5 mg/m2 and a median weekly dose of MTX 8.3 mg/m2. …”

Conventional medical management of inflammatory bowel disease. by Burger, D, Travis, S

“…Common mistakes in conventional therapy include overprescription of mesalamine for CD; inappropriate use of steroids (for perianal CD, when there is sepsis, or for maintenance); delayed introduction or underdosing with azathioprine, 6-mercaptopurine, or methotrexate; and failure to consider timely surgery. …”

Systematic review: does concurrent therapy with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes? by Andrews, J, Travis, S, Gibson, P, Gasche, C

“…METHODS: Systematic review with search terms 'azathioprine, 6-mercaptopurine, thiopurine(s), 5 aminosalicylic acid, mesalazine, inflammatory bowel disease, ulcerative colitis, Crohn's disease, immunosuppressant(s), immunomodulator and methotrexate' in November 2007 to identify clinical trials on concurrent 5-ASA and immunomodulator therapy. …”

The impact of risk stratification by early bone-marrow response in childhood lymphoblastic leukaemia: results from the United Kingdom Medical Research Council trial ALL97 and ALL97... by Mitchell, C, Payne, J, Wade, R, Vora, A, Kinsey, S, Richards, S, Eden, T

“…The 1997 acute lymphoblastic leukaemia (ALL) trial (ALL97) was a randomised comparison of prednisolone versus dexamethasone and of 6-mercaptopurine versus 6-thioguanine. During the first 2 years of the trial, review of survival data showed the preceding trial, UKALL XI, was no better than its predecessor and that survival for childhood ALL in the UK had not improved in the fashion witnessed by other cooperative treatment groups. …”

Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia. by McLeod, H, Coulthard, S, Thomas, A, Pritchard, S, King, D, Richards, S, Eden, O, Hall, A, Gibson, B

“…The role of 6-mercaptopurine (6MP) in the treatment of childhood acute lymphoblastic leukaemia (ALL) is well established. …”

Medical Research Council leukaemia trial--UKALL V: an attempt to reduce the immunosuppressive effects of therapy in childhood acute lymphoblastic leukemia. Report to the Council by... by Chessells, J, Durrant, J, Hardy, R, Richards, S

“…All 496 children were randomized to receive chemotherapy for 2 or 3 years with 6-mercaptopurine and methotrexate either as a continuous (group C) or a semicontinuous (group G) regimen or as a five-day pulse every 3 weeks (group I). …”